VJHemOnc is committed to improving our service to you

EHA 2019 | A new HORIZON: melflufen for R/R multiple myeloma

VJHemOnc is committed to improving our service to you

Paul Richardson

Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, tells us about the use of melflufen in the treatment of relapsed/refractory multiple myeloma. Dr Richardson also mentions the HORIZON study (NCT02963493), which evaluated melflufen in combination with dexamethasone in the treatment of R/R multiple myeloma in adult patients with disease refractory to pomalidomide and/or daratumumab. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

aminopeptidase activated, lipophilic

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter